Related Experiment Video
Updated: May 9, 2025
08:03
Intracavernosal Pressure Recording to Evaluate Erectile Function in Rodents
Published on: June 6, 2018
14.1K
Procyanidin Improves Erectile Function in Rats by Inhibiting PDE5A Activity
Yudong Su1,2, Jinman Shui1, Danshi Qi1
1School of Pharmacy, Qinghai University, Xining, Qinghai, People's Republic of China.
Drug Design, Development and Therapy
|May 5, 2025
Summary
Procyanidin effectively inhibits PDE5A, increasing cGMP levels and improving erectile function. This natural compound shows promise as a safe and effective treatment for erectile dysfunction (ED).
Area of Science:
- Biochemistry and Pharmacology
- Natural Product Chemistry
Background:
- Erectile dysfunction (ED) is a common condition primarily treated with Phosphodiesterase type 5 inhibitors (PDE5Is).
- Previous research identified procyanidin, a natural compound, as a potent PDE5I.
Purpose of the Study:
- To validate the inhibitory activity of procyanidin on Phosphodiesterase type 5 A (PDE5A) through in vitro and in vivo experiments.
- To assess the therapeutic efficacy of procyanidin as a treatment for erectile dysfunction.
Main Methods:
- Molecular docking, molecular dynamics (MD) simulations, and microscale thermophoresis (MST) were used to assess procyanidin's binding affinity to PDE5A.
- Cytotoxicity of procyanidin on penile corpus cavernosum smooth muscle (CCSM) cells and its effect on intracellular cyclic guanosine monophosphate (cGMP) levels were evaluated.
- In vivo studies in Sprague-Dawley (SD) rats assessed procyanidin absorption, its effects on intracavernous pressure (ICP), and penile cGMP levels.
Main Results:
- Procyanidin demonstrated strong binding to PDE5A, stabilizing the complex and exhibiting an equilibrium dissociation constant (KD) of 7.77 ± 2.39 µmol/L.
- Procyanidin showed minimal cytotoxicity to CCSM cells and significantly increased intracellular cGMP levels.
- In vivo, procyanidin was rapidly absorbed, significantly increased ICP and penile cGMP levels in rats, confirming its efficacy.
Conclusions:
- Procyanidin sustains elevated cGMP levels by inhibiting PDE5A, demonstrating therapeutic potential for erectile dysfunction.
- Procyanidin is a promising natural PDE5I for treating ED and related conditions, with demonstrated safety and efficacy.
Related Concept Videos
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
85
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
85
01:28Nitric Oxide Signaling Pathway
4.8K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
4.8K
01:23Antihypertensive Drugs: Vasodilators
426
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
426
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
97
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
97
01:16Antianginal Drugs: Nitrates and β-Blockers
432
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
432
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
302
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
302